Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents

Bibliography

• Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95
   PubMed Web of Science ®Google Scholar
• Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009;361:2153-64
   PubMed Web of Science ®Google Scholar
• Kaski JK, Haywood C, Mahida S, et al. Oxford handbook of drugs in cardiology. 1st edition. Oxford University Press, Oxford, UK; 2010. p. 1-729
   Google Scholar
• Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 2013; In press
   Web of Science ®Google Scholar
• Shankar SS, Brater C. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003;284:F11-21
   PubMed Web of Science ®Google Scholar
• Haas M, Forbush B III. The Na-K-Cl cotransporter of secretory epithelia. Annu Rev Physiol 2000;62:515-34
   PubMed Web of Science ®Google Scholar
• Orlov SN, Tremblay J, Hamet P. NKCC1 and hypertension: a novel therapeutic target involved in the regulation of vascular tone and renal function. Curr Opin Nephrol Hypertens 2010;19:163-8
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357
   PubMed Web of Science ®Google Scholar
• Dormans TP, Pickkers P, Russel FG, Smits P. Vascular effects of loop diuretics. Cardiovasc Res 1996;32:988-97
   PubMed Web of Science ®Google Scholar
• de Berrazueta JR, González JP, de Mier I, et al. Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. J Cardiovasc Pharmacol 2007;49:90-5
   PubMed Web of Science ®Google Scholar
• Chun TY, Bankir L, Eckert GJ, et al. Ethnic differences in renal responses to furosemide. Hypertension 2008;52:241-8
   PubMed Web of Science ®Google Scholar
• Finnerty FA Jr, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension: a two-year comparison of efficacy and safety. Angiology 1977;28:125-33
   PubMed Web of Science ®Google Scholar
• Healy JJ, McKenna TJ, Canning BS, et al. Body composition changes in hypertensive subjects on long-term oral diuretic therapy. Br Med J 1970;1:716-19
   PubMed Web of Science ®Google Scholar
• Musini VM, Rezapour P, Wright JM, et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2012;8:CD003825
   Google Scholar
• Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999;19:581-97
   PubMed Web of Science ®Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure - activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6
   PubMed Web of Science ®Google Scholar
• Sica DA, Moser M. Diuretic therapy in cardiovascular disease. In: Black HR, Elliott WJ, editors, Hypertension: a companion to Braunwald's heart disease. W.B. Saunders, Philadelphia; 2007
   Google Scholar
• K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(Suppl 1):S1-290
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
   PubMed Web of Science ®Google Scholar
• Broekhuysen J, Deger F, Douchamps J, et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol 1986;31:29-34
   PubMed Web of Science ®Google Scholar
• Fortuño A, Muñiz P, Ravassa S, et al. Torasemide inhibits angiotensin-II induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999;34:138-43
   PubMed Web of Science ®Google Scholar
• Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991;205(2):145-50
   PubMed Web of Science ®Google Scholar
• Cosin J, Diez J, on behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4:507-13
   PubMed Web of Science ®Google Scholar
• Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-35
   PubMed Web of Science ®Google Scholar
• Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006;92:1434-40
   PubMed Web of Science ®Google Scholar
• Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57:601-9
   PubMed Web of Science ®Google Scholar
• Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111:513-20
   PubMed Web of Science ®Google Scholar
• Masuyama T, Tsujino T, Origasa H, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 2012;76:833-42
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Strait KM, Dharmarajan K, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol 2013;61:1549-50
   PubMed Web of Science ®Google Scholar
• Schwartz S, Brater DC, Pound D, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993;54:90-7
   PubMed Web of Science ®Google Scholar
• Van Meyel JJ, Gerlag PG, Smits P, et al. Absorption of high dose furosemide (frusemide) in congestive heart failure. Clin Pharmacokinet 1992;22:308-18
   PubMed Web of Science ®Google Scholar
• Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 1981;20:27-33
   PubMed Web of Science ®Google Scholar
• Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987;32:572-8
   PubMed Web of Science ®Google Scholar
• Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studied Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-8
   PubMed Web of Science ®Google Scholar
• Baxter K, Preston CL. editors. Stockley´s drug interactions. 10th edition. Pharmaceutical Press, London; 2013
   Google Scholar
• Juurlink DN, Mamdani MM, Kopp A. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004;52:794-8
   PubMed Web of Science ®Google Scholar
• Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007;113:267-78
   PubMed Web of Science ®Google Scholar
• Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010;6:261-73
   PubMed Web of Science ®Google Scholar
• Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012;33:2782-95
   PubMed Web of Science ®Google Scholar
• McManus F, McInnes GT, Connell JM. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab 2008;4:44-52
   PubMedGoogle Scholar
• Teiwes J, Toto RD. Epithelial sodium channel inhibition in cardiovascular disease: a potential role for amiloride. Am J Hypertens 2007;20:109-17
   PubMed Web of Science ®Google Scholar
• Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891-4
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S, et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45
   PubMed Web of Science ®Google Scholar
• Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15:333-9
   PubMed Web of Science ®Google Scholar
• Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-64
   PubMedGoogle Scholar
• Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 2013;31:3-15
   PubMed Web of Science ®Google Scholar
• Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005;10:23-9
   PubMed Web of Science ®Google Scholar
• Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008;168:80-5
   PubMedGoogle Scholar
• Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008;9:509-15
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980-90
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16
   PubMed Web of Science ®Google Scholar
• Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982;49:1561-3
   PubMed Web of Science ®Google Scholar
• Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30
   PubMed Web of Science ®Google Scholar
• Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev 2010;(8):CD008169
   Google Scholar
• Burgess ED, Lacourcière Y, Ruilope-Urioste LM, et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003;25:2388-404
   PubMed Web of Science ®Google Scholar
• Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55
   PubMed Web of Science ®Google Scholar
• Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005;150:426-33
   PubMed Web of Science ®Google Scholar
• Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-8
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004;66:1-9
   PubMed Web of Science ®Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005;28:2106-12
   PubMed Web of Science ®Google Scholar
• Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-51
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:542-51
   PubMed Web of Science ®Google Scholar
• Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002;40:647-52
   PubMed Web of Science ®Google Scholar
• Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007;25:2345-51
   PubMed Web of Science ®Google Scholar
• Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010;152:78-84
   PubMed Web of Science ®Google Scholar
• Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012;59:1598-603
   PubMed Web of Science ®Google Scholar
• Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009;2:370-6
   PubMed Web of Science ®Google Scholar
• Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-7
   PubMed Web of Science ®Google Scholar
• Baker EH, Duggal A, Dong Y, et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension 2002;40:13-17
   PubMed Web of Science ®Google Scholar
• Rayner BL, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006;19:208-13
   PubMed Web of Science ®Google Scholar
• Ravis WR, Reid S, Sica DA, et al. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005;45:810-21
   PubMed Web of Science ®Google Scholar
• Gulmez SE, Lassen AT, Aalykke C, et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008;66:294-9
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW, Yancy C. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail 2003;9:224-9
   PubMedGoogle Scholar
• Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008;29:2171-9
   PubMed Web of Science ®Google Scholar
• Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008;51:742-8
   PubMed Web of Science ®Google Scholar
• Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010;285:29932-40
   PubMed Web of Science ®Google Scholar
• Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012;7:1385-403
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Kretschmer A, Baerfacker L, et al. Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist. Eur Heart J 2012;33(Suppl):abstract 978
   Google Scholar
• Delbeck M, Kretschmer A, Kast R, et al. Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure. Eur Heart J 2012;33(Suppl):abstract 772
   Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34:2453-63
   PubMed Web of Science ®Google Scholar
• Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant 2013;28:36-43
   PubMed Web of Science ®Google Scholar
• Amar L, Azizi M, Menard J, et al. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens 2013;31:624-9
   PubMed Web of Science ®Google Scholar
• Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011;124:1945-55
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile J, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens 2010;4:42-50
   PubMed Web of Science ®Google Scholar
• Stears AJ, Woods SH, Watts MM, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension 2012;59:934-42
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 2003;16:1036-42
   PubMed Web of Science ®Google Scholar
• Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327-37
   PubMed Web of Science ®Google Scholar